Literature DB >> 9071487

Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome.

W E Kaufmann1, P F Worley, C V Taylor, M Bremer, P C Isakson.   

Abstract

Cyclooxygenase or prostaglandin endoperoxide H synthase-2 (PGHS-2) is the first enzyme in the prostanoid biosynthetic pathways and, in brain, it is regulated as an immediate-early gene (IEG). PGHS-2 mRNA and protein are rapidly induced by physiological synaptic activity, and high basal expression in cerebral cortex appears to be maintained by the natural synaptic activity. In contrast to other IEGs, PGHS-2 is a dendritic protein that is enriched in dendritic spines and is, therefore, likely to play a direct role in synaptic physiology. Consistent with a signaling function in mature dendritic spines, PGHS-2 expression is strongly regulated during normal postnatal development in the rat, with peak expression during the third and fourth weeks. Here we use immunocytochemical approaches to compare the developmental expression of PGHS-2 in rat neocortex with that of other well characterized markers of dendritic maturation. PGHS-2 immunoreactivity (ir) follows histogenetic gradients and expression in secondary or more distal dendrites postdates that of even the most delayed dendritic proteins. This developmental pattern parallels the critical period for somatosensory and visual cortex development. Accordingly, PGHS-2-ir may be a useful marker of the final activity-dependent stages of cortical development. Consistent with the potential histochemical utility, we demonstrate that the normal laminar pattern of PGHS-2-ir in human cortex is altered in patients with Rett syndrome, a form of mental retardation with known alterations of dendritic maturation. Further studies of the developmental expression of PGHS-2 in human cortical development may permit analyses of dendritic abnormalities, in syndromes associated with disturbances of activity-dependent development, as well as provide an anatomic basis for understanding the role of prostaglandin signaling in cortical development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071487     DOI: 10.1016/s0387-7604(96)00047-2

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  11 in total

Review 1.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

Review 2.  Transient receptor potential channels as novel effectors of brain-derived neurotrophic factor signaling: potential implications for Rett syndrome.

Authors:  Michelle D Amaral; Christopher A Chapleau; Lucas Pozzo-Miller
Journal:  Pharmacol Ther       Date:  2006-11-21       Impact factor: 12.310

Review 3.  Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation.

Authors:  Yeon-Joo Kang; Uri R Mbonye; Cynthia J DeLong; Masayuki Wada; William L Smith
Journal:  Prog Lipid Res       Date:  2007-01-18       Impact factor: 16.195

4.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

5.  Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.

Authors:  Anil Kumar; Beenta Kumari; Puneet Kumar
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

Review 6.  Experimental models of Rett syndrome based on Mecp2 dysfunction.

Authors:  Gaston Calfa; Alan K Percy; Lucas Pozzo-Miller
Journal:  Exp Biol Med (Maywood)       Date:  2011-01

7.  Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.

Authors:  Jennifer L Larimore; Christopher A Chapleau; Shinichi Kudo; Anne Theibert; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-01-03       Impact factor: 5.996

8.  Selective cerebral volume reduction in Rett syndrome: a multiple-approach MR imaging study.

Authors:  J C Carter; D C Lanham; D Pham; G Bibat; S Naidu; W E Kaufmann
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-07       Impact factor: 3.825

9.  Comparison of pharmacological and genetic inhibition of cyclooxygenase-2: effects on adult neurogenesis in the hippocampal dentate gyrus.

Authors:  Sung Min Nam; Jong Whi Kim; Dae Young Yoo; Jung Hoon Choi; Woosuk Kim; Hyo Young Jung; Moo-Ho Won; In Koo Hwang; Je Kyung Seong; Yeo Sung Yoon
Journal:  J Vet Sci       Date:  2014-12-24       Impact factor: 1.672

10.  Risk management profile of etoricoxib: an example of personalized medicine.

Authors:  Paola Patrignani; Stefania Tacconelli; Marta L Capone
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.